Prescribing Qlosi, a pharmaceutical eye drop treatment for presbyopia, does not appear to negatively impact optical sales or reduce the frequency of patient visits to eye care practices. A recent study evaluating clinical performance metrics suggests that the introduction of pharmacological management for age-related near-vision loss functions as a complementary service rather than a replacement for traditional corrective eyewear, according to findings discussed by industry professionals.
The study, which examined data from West Point Optical Group, addressed concerns among optometrists regarding whether the adoption of such drops would lead to a “cannibalization” of their optical revenue. Harmin J. Chima, OD, FAAO, vice president of professional services at West Point Optical Group, noted that clinicians frequently questioned if the drops would discourage patients from purchasing glasses or reduce the number of billable encounters. The findings indicate that these concerns were not supported by the practice’s operational data, as reported in industry coverage of the FDA-approved treatment for presbyopia.
Evaluating the Impact on Optical Practice Revenue
For independent and group optometry practices, the primary economic concern regarding new medical therapies for presbyopia has been the potential loss of revenue from high-margin optical goods. The investigation into the use of Qlosi—a phentolamine ophthalmic solution—sought to quantify whether patients who received prescriptions for the drops subsequently opted out of purchasing frames or lenses. According to the data presented by West Point Optical Group, there was no statistically significant reduction in optical sales volume following the integration of the drops into their clinical protocols.
This suggests that the patient demographic seeking pharmacological intervention for presbyopia may overlap with, but does not necessarily displace, those requiring traditional refractive correction. The American Optometric Association defines presbyopia as the gradual loss of the eye’s ability to focus on nearby objects, a condition typically managed with multifocal lenses or reading glasses. By providing an alternative that addresses the physiological symptoms, practitioners may be expanding their service offerings rather than substituting one revenue stream for another.
Clinical Integration and Patient Encounters
Beyond sales, clinicians expressed concern that the time required to manage, monitor, and prescribe pharmaceutical drops might reduce the overall capacity for patient throughput. The study found that billable encounters remained stable, suggesting that the incorporation of Qlosi did not create an unsustainable administrative or clinical burden that would force a reduction in patient volume. For many practices, the ability to offer a medical solution for presbyopia provides a new avenue for patient engagement, potentially increasing the frequency with which patients return for follow-up care.
Orasis Pharmaceuticals, the developer of the drop, collaborated with clinical groups to observe these real-world outcomes. This partnership aimed to provide data-driven answers to the questions practitioners faced regarding the long-term viability of incorporating pharmaceutical eye drops into a traditional optical retail environment. By analyzing these metrics, practices can better understand how to balance their medical and retail operations as new ophthalmic technologies continue to enter the market.
What This Means for Future Presbyopia Care
The findings offer a template for how optometry practices might adapt to the evolving landscape of vision correction. As pharmaceutical options for common refractive conditions become more prevalent, the integration of these therapies is likely to become a standard consideration for clinical management. The evidence provided by the West Point Optical Group study indicates that such medical advancements can coexist with traditional optical services, potentially enhancing the overall value proposition for the patient.
Clinicians interested in the ongoing monitoring of these trends can look to official updates from the American Academy of Ophthalmology regarding clinical practice guidelines. As more data becomes available, it is expected that further studies will continue to refine the understanding of how pharmacological treatments interact with traditional optical care models. Practitioners are encouraged to review their own internal performance data and participate in professional discussions to stay informed on best practices for managing this transition in eye care services.
Readers are invited to share their experiences regarding the integration of new ophthalmic therapies in their local practices or to join the discussion on the impact of medical innovation in optometry in the comments section below.